Finance leaders have a timely opportunity to enhance liquidity, reduce tax burdens and align tax policy with business growth.

Join the Future of Work & the Innovation Economy initiative to discuss the concern about indirect costs, the FAIR model, and ...

The U.S. Capitol in Washington, DC. A bipartisan group of lawmakers has reintroduced legislation to allow immediate expensing of research and development costs, all the way back to 2022 when the tax ...

The new Section 174A that came out of the One Big Beautiful Bill Act establishes different rules for past and future research and development spending — creating an opportunity for advisors. For tax ...

The most popular consumer internet services usually figure out how to make money even after a decade or more of losses.

As competition in the artificial intelligence industry intensifies, OpenAI has decided to invest $350 billion by 2030, focusing on computing power and research and development. This massive investment ...

The 2025 OBBB Act restores immediate expensing for U.S.-based R&D while foreign R&D requires 15-year amortization. Companies can claim catch-up deductions for 2022-2024 domestic expenses, with R&D tax ...

Tustin-based Peregrine Pharmaceuticals Inc. said Friday that higher research and staffing costs led to a larger loss in the quarter ended Oct. 31. Peregrine, which is developing drugs to treat ...

The obesity market is driving pharma’s return on investment (ROI) upward, with the projected return rising to 5.9% overall in 2024, but only reaching 3.8% if GLP-1 assets are excluded. At the same ...

Keysight raised its full-year outlook, now expecting fiscal fourth-quarter revenue between $1.37 billion and $1.39 billion and earnings per share of $1.79 to $1.85. The price of Keysight stock (NYSE: ...